192 related articles for article (PubMed ID: 17375681)
1. [Antipsychotics--clever choices].
Ek M; Lindefors N
Lakartidningen; 2007 Feb 14-20; 104(7):504-8. PubMed ID: 17375681
[No Abstract] [Full Text] [Related]
2. Glucose intolerance with atypical antipsychotics.
Hedenmalm K; Hägg S; Ståhl M; Mortimer O; Spigset O
Drug Saf; 2002; 25(15):1107-16. PubMed ID: 12452735
[TBL] [Abstract][Full Text] [Related]
3. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
Volavka J; Czobor P; Cooper TB; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA
J Clin Psychiatry; 2004 Jan; 65(1):57-61. PubMed ID: 14744169
[TBL] [Abstract][Full Text] [Related]
4. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Mosolov SN; Kabanov SO
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
[No Abstract] [Full Text] [Related]
5. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
[TBL] [Abstract][Full Text] [Related]
7. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
Strassnig M; Miewald J; Keshavan M; Ganguli R
Schizophr Res; 2007 Jul; 93(1-3):90-8. PubMed ID: 17478082
[TBL] [Abstract][Full Text] [Related]
8. Novel antipsychotics: comparison of weight gain liabilities.
Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
[TBL] [Abstract][Full Text] [Related]
9. What CATIE found: results from the schizophrenia trial.
Swartz MS; Stroup TS; McEvoy JP; Davis SM; Rosenheck RA; Keefe RS; Hsiao JK; Lieberman JA
Psychiatr Serv; 2008 May; 59(5):500-6. PubMed ID: 18451005
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
Ramsey TL; Brennan MD
Schizophr Res; 2014 Dec; 160(1-3):73-9. PubMed ID: 25449714
[TBL] [Abstract][Full Text] [Related]
11. The effects of novel antipsychotics on glucose and lipid levels.
Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC
J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594
[TBL] [Abstract][Full Text] [Related]
12. Clinical experiences and clinical trials.
Fusar-Poli RR
CNS Spectr; 2008 Jun; 13(6):461-2; author reply 462-3. PubMed ID: 18567969
[No Abstract] [Full Text] [Related]
13. Comparative effectiveness of antipsychotic drugs.
Meibach RC
Am J Psychiatry; 2003 Mar; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
[No Abstract] [Full Text] [Related]
14. Agranulocytosis and neutropenia with typical and atypical neuroleptics.
Hong X; Wang X
Am J Psychiatry; 2001 Oct; 158(10):1736-7. PubMed ID: 11579015
[No Abstract] [Full Text] [Related]
15. Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.
Miyamoto S; Miyake N; Ogino S; Endo T; Yamaguchi N
Psychiatry Clin Neurosci; 2007 Dec; 61(6):702-3. PubMed ID: 18081639
[No Abstract] [Full Text] [Related]
16. Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Peuskens J; Gillain B; De Graeve D; Van Vleymen B; Albert A
Eur Psychiatry; 2009 Apr; 24(3):154-63. PubMed ID: 19118983
[TBL] [Abstract][Full Text] [Related]
17. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
18. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
19. Weight gain and antipsychotic medications.
Aquila R; Emanuel M
J Clin Psychiatry; 1999 May; 60(5):336-7. PubMed ID: 10362443
[No Abstract] [Full Text] [Related]
20. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Bobes J; Rejas J; Garcia-Garcia M; Rico-Villademoros F; García-Portilla MP; Fernández I; Hernández G;
Schizophr Res; 2003 Jul; 62(1-2):77-88. PubMed ID: 12765747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]